
News|Articles|August 1, 2004
Ezetimibe/simvastatin
This novel dyslipidemia therapy features a combination of 2 previously approved drugs: ezetimibe and simvastatin. Ezetimibe exerts its effect by selectively inhibiting intestinal cholesterol and related phytosterol absorption. This mechanism of action is complemented by that of simvastatin, which acts through inhibition of the HMG-CoA reductase enzyme. The ezetimibe/simvastatin combination was approved on July 23, 2004, for the treatment of hypercholesterolemia and mixed hyperlipidemia
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Rural health is ailing. Is $50 billion enough to heal it?
2
GLP-1 medications are linked to hair loss in Type 2 diabetes
3
Recombinant shingles vaccine linked to lower cardiovascular disease risk
4
FDA clears Mimrylo, a first-in-class therapy for polycythemia vera
5























